PDCD1 and cancer: The unprecedented and durable response rates described recently in a remarkable percentage of cancer patients, including treatment-refractory patients with advanced cancers, have allowed since 2011, the approval by US Food and Drug Administration (FDA) of several inhibitors of PD-1/PD-L1 axis in many cancers (126).